Veracyte Inc (VCYT) 9.63 $VCYT
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 23, 12:25PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AMSC: 6.88 (-3.12), VCYT: 9.63 (+0.40), ASPS: 23.24 (+0.76), OFLX: 29.59 (+0.39), SCYX: 9.47 (-0.52), ANGI: 6.16 (-0.24), VASC: 35.31 (+0.45), PKT: 11.43 (-0.02), GLUU: 5.45 (+0.09), ASML: 107.16 (-1.53), DWCH: 7.76 (-0.34)
Veracyte, Inc. Announces $40 Million Private Placement
PR Newswire - Thu Apr 23, 8:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that it has entered into a definitive agreement to sell approximately $40 million of its common stock in a private placement. Under the agreement, the investors will purchase an aggregate of 4,907,975 shares of common stock at a purchase price of $8.15 per share, the closing stock price on April 22, 2015. The private placement was led by new and existing investors, including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners and venBio, among others.
VCYT: 9.63 (+0.40)
Veracyte Initiates Launch of Percepta(TM) Bronchial Genomic Classifier to Improve Lung Cancer Diagnosis
PR Newswire - Thu Apr 16, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostic company pioneering the field of molecular cytology, today announced the launch of its Percepta(TM) Bronchial Genomic Classifier, a new genomic test to resolve ambiguity in lung cancer diagnosis. The company will soon begin testing patient samples in its CLIA-certified laboratory, with the Percepta test now available to a limited number of institutions around the country.
VCYT: 9.63 (+0.40)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 158.99 (-0.67), COO: 181.75 (-1.24), SNN: 35.76 (+0.44), VCYT: 9.63 (+0.40), ABAX: 63.62 (+0.31), DYSL: 1.40 (unch), VOLC: 17.99 (+0.01), CLLS: 32.61 (-0.07), COHR: 65.14 (-1.57), HRC: 51.94 (+0.03)
Veracyte and GE Announce Research Collaboration
PR Newswire - Tue Apr 14, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostic company pioneering the field of molecular cytology, and GE today announced a research collaboration to develop new solutions that can improve disease diagnosis. Financial and other terms were not disclosed.
GE: 26.80 (-0.05), VCYT: 9.63 (+0.40)
U.S. Thyroid Cancer Market: Trends and Opportunities (2015 - 2019)
M2 - Thu Apr 09, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w48tkb/u_s_thyroid) has announced the addition of the "U.S. Thyroid Cancer Market: Trends and Opportunities (2015 - 2019)" report to their offering. The report US Thyroid Cancer Market: Trends and Opportunities (2015-2019) provides an insight into the overall thyroid cancer market of the United States of America. The report analyzes in detail the segments of Thyroid Cancer Market that includes Thyroid Cancer Diagnostics Surgeries, Thyroid Histopathology Market, Thyroid Cancer Secondary Surgery and Thyroid Cancer Hormone Replacement Market. The report assesses thyroid cancer types, stages and incidence rate of the disease and also discusses the factors that will result in the demand and growth of the market. Thyroid cancer, a type of malignant cancer, initiate from follicular and par follicular thyroid cells. The most effective treatment of thyroid cancer is surgical removal of thyroid gland followed by radioactive ablation and thyroid stimulating hormone (TSH) suppression therapy. Chemotherapy is also used in cases of metastasis and progressive stage of thyroid cancer. Thyroid cancer market is accelerating in the United States since 2010 and it is a disease which is fast on the rise. Incidence has more than doubled since the early 1970s, and for women, it is the cancer with the fastest-growing number of new cases. On the back of high incidence of thyroid cancer, it is anticipated that the thyroid cancer market in US will observe impressive double digit growth in next five years. The thyroid cancer diagnosis market is segmented into diagnostic surgeries, histopathology, secondary surgery and annual new patient hormone replacement therapy. The diagnostic technology has improved since 2011 and with use of Afirma GEC test and Afirma FNA; the detection of even minor nodules has become possible. Product Coverage - Thyroid Cancer Diagnostic Surgeries - Thyroid Cancer Histopathology Market - Thyroid Cancer Secondary Surgery - Thyroid Cancer Hormone Replacement - FNA biopsies Key Topics Covered: 1. Executive Summary 2. United States Thyroid Cancer Market: An Introduction 3. US Thyroid Cancer Market: Sizing and Growth 4. US Thyroid Cancer Market Segmentation 5. U.S Thyroid Cancer Diagnosis Market: By FNA volume 6. Market Dynamics: US Thyroid Cancer Diagnosis Market 7. Competitive Landscape: U.S Thyroid Cancer Diagnosis Market 8. Company Profiles: U.S Thyroid Cancer Diagnosis Market - Abbott Laboratories - Forest Laboratories - Mylan Inc. - Oxigene Inc. - Veracyte Inc. For more information visit http://www.researchandmarkets.com/research/w4..._s_thyroid
OXGN: 1.48 (unch), ABT: 48.32 (-0.14), VCYT: 9.63 (+0.40)
Veracyte ups revenues 79% in Q4
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 5:35AM CDT
VCYT: 9.63 (+0.40)
Veracyte's (VCYT) CEO Bonnie Anderson on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 19, 10:03PM CDT
VCYT: 9.63 (+0.40)
Veracyte reports 4Q loss
Automated Insights - Thu Mar 19, 3:24PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Thursday reported a loss of $8.1 million in its fourth quarter.
VCYT: 9.63 (+0.40)
Veracyte misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 3:13PM CDT
VCYT: 9.63 (+0.40)
Veracyte, Inc. Announces Fourth Quarter and Full-Year 2014 Financial Results, Provides 2015 Financial Outlook
PR Newswire - Thu Mar 19, 3:05PM CDT
Veracyte, Inc. (Nasdaq: VCYT) today reported financial results and business progress for the quarter and full year ended December 31, 2014, and provided financial guidance for 2015.
VCYT: 9.63 (+0.40)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.05), VRTX: 133.20 (-2.62), CERU: 6.27 (+0.07), FOMX: 10.46 (-0.44), ONTX: 2.34 (-0.05), PFNX: 15.80 (-0.20), OMER: 24.32 (-0.35), PGNX: 6.03 (-0.38), SYN: 2.33 (+0.01), VCYT: 9.63 (+0.40), STEM: 0.61 (-0.21), APRI: 1.61 (-0.13), KPTI: 31.49 (-1.13)
Veracyte, Inc. to Announce Fourth Quarter and Full-Year 2014 Financial Results and Host Conference Call and Webcast on Thursday, March 19, 2015
PR Newswire - Thu Mar 12, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2014 financial results after close of market on Thursday, March 19, 2015. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and business progress.
VCYT: 9.63 (+0.40)
Veracyte Announces Publication of Data Demonstrating Analytical and Clinical Validity of Its Afirma® BRAF Malignancy Classifier
PR Newswire - Thu Feb 05, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of data demonstrating the analytical and clinical validity of Afirma® BRAF, the company's malignancy classifier for identifying BRAF V600E mutation status among thyroid nodule biopsies. The data, which appear in the current issue of Pacific Symposium on Biocomputing, confirm that the Afirma RNA-based classifier detects the BRAF V600E mutation with high diagnostic accuracy.
VCYT: 9.63 (+0.40)
Veracyte to Present at the Leerink Partners 2015 Global Healthcare Conference
PR Newswire - Wed Feb 04, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat discussion at the Leerink Partners 2015 Global Healthcare Conference on Wednesday, February 11, 2015 at 11:30 a.m. ET in New York, NY.
VCYT: 9.63 (+0.40)
5 Stocks Ready for Breakouts: Veracyte, Flextronics and More
at The Street - Fri Jan 30, 5:00AM CST
These stocks look poised to break out and trade higher from current levels.
FLEX: 12.35 (-0.18), EXXI: 4.16 (+0.06), VCYT: 9.63 (+0.40), XGTI: 0.21 (unch), RGLS: 17.49 (-0.80)
Veracyte, Inc. Names Dr. Robert S. Epstein to Its Board of Directors
PR Newswire - Mon Jan 12, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointment of Robert S. Epstein, M.D., M.S., to its Board of Directors.
VCYT: 9.63 (+0.40), ILMN: 189.59 (-3.01)
Veracyte to Present at the J.P. Morgan 33rd Annual Healthcare Conference
PR Newswire - Thu Jan 08, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the J.P. Morgan 33rd Annual Healthcare Conference on Thursday, January 15, 2015, at 8:30 a.m. Pacific Time in San Francisco, Calif.
VCYT: 9.63 (+0.40), JPM: 62.60 (-0.20)
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 23, 12:25PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AMSC: 6.88 (-3.12), VCYT: 9.63 (+0.40), ASPS: 23.24 (+0.76), OFLX: 29.59 (+0.39), SCYX: 9.47 (-0.52), ANGI: 6.16 (-0.24), VASC: 35.31 (+0.45), PKT: 11.43 (-0.02), GLUU: 5.45 (+0.09), ASML: 107.16 (-1.53), DWCH: 7.76 (-0.34)
Veracyte, Inc. Announces $40 Million Private Placement
PR Newswire - Thu Apr 23, 8:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that it has entered into a definitive agreement to sell approximately $40 million of its common stock in a private placement. Under the agreement, the investors will purchase an aggregate of 4,907,975 shares of common stock at a purchase price of $8.15 per share, the closing stock price on April 22, 2015. The private placement was led by new and existing investors, including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners and venBio, among others.
VCYT: 9.63 (+0.40)
Veracyte Initiates Launch of Percepta(TM) Bronchial Genomic Classifier to Improve Lung Cancer Diagnosis
PR Newswire - Thu Apr 16, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostic company pioneering the field of molecular cytology, today announced the launch of its Percepta(TM) Bronchial Genomic Classifier, a new genomic test to resolve ambiguity in lung cancer diagnosis. The company will soon begin testing patient samples in its CLIA-certified laboratory, with the Percepta test now available to a limited number of institutions around the country.
VCYT: 9.63 (+0.40)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 158.99 (-0.67), COO: 181.75 (-1.24), SNN: 35.76 (+0.44), VCYT: 9.63 (+0.40), ABAX: 63.62 (+0.31), DYSL: 1.40 (unch), VOLC: 17.99 (+0.01), CLLS: 32.61 (-0.07), COHR: 65.14 (-1.57), HRC: 51.94 (+0.03)
Veracyte and GE Announce Research Collaboration
PR Newswire - Tue Apr 14, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostic company pioneering the field of molecular cytology, and GE today announced a research collaboration to develop new solutions that can improve disease diagnosis. Financial and other terms were not disclosed.
GE: 26.80 (-0.05), VCYT: 9.63 (+0.40)
U.S. Thyroid Cancer Market: Trends and Opportunities (2015 - 2019)
M2 - Thu Apr 09, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w48tkb/u_s_thyroid) has announced the addition of the "U.S. Thyroid Cancer Market: Trends and Opportunities (2015 - 2019)" report to their offering. The report US Thyroid Cancer Market: Trends and Opportunities (2015-2019) provides an insight into the overall thyroid cancer market of the United States of America. The report analyzes in detail the segments of Thyroid Cancer Market that includes Thyroid Cancer Diagnostics Surgeries, Thyroid Histopathology Market, Thyroid Cancer Secondary Surgery and Thyroid Cancer Hormone Replacement Market. The report assesses thyroid cancer types, stages and incidence rate of the disease and also discusses the factors that will result in the demand and growth of the market. Thyroid cancer, a type of malignant cancer, initiate from follicular and par follicular thyroid cells. The most effective treatment of thyroid cancer is surgical removal of thyroid gland followed by radioactive ablation and thyroid stimulating hormone (TSH) suppression therapy. Chemotherapy is also used in cases of metastasis and progressive stage of thyroid cancer. Thyroid cancer market is accelerating in the United States since 2010 and it is a disease which is fast on the rise. Incidence has more than doubled since the early 1970s, and for women, it is the cancer with the fastest-growing number of new cases. On the back of high incidence of thyroid cancer, it is anticipated that the thyroid cancer market in US will observe impressive double digit growth in next five years. The thyroid cancer diagnosis market is segmented into diagnostic surgeries, histopathology, secondary surgery and annual new patient hormone replacement therapy. The diagnostic technology has improved since 2011 and with use of Afirma GEC test and Afirma FNA; the detection of even minor nodules has become possible. Product Coverage - Thyroid Cancer Diagnostic Surgeries - Thyroid Cancer Histopathology Market - Thyroid Cancer Secondary Surgery - Thyroid Cancer Hormone Replacement - FNA biopsies Key Topics Covered: 1. Executive Summary 2. United States Thyroid Cancer Market: An Introduction 3. US Thyroid Cancer Market: Sizing and Growth 4. US Thyroid Cancer Market Segmentation 5. U.S Thyroid Cancer Diagnosis Market: By FNA volume 6. Market Dynamics: US Thyroid Cancer Diagnosis Market 7. Competitive Landscape: U.S Thyroid Cancer Diagnosis Market 8. Company Profiles: U.S Thyroid Cancer Diagnosis Market - Abbott Laboratories - Forest Laboratories - Mylan Inc. - Oxigene Inc. - Veracyte Inc. For more information visit http://www.researchandmarkets.com/research/w4..._s_thyroid
OXGN: 1.48 (unch), ABT: 48.32 (-0.14), VCYT: 9.63 (+0.40)
Veracyte ups revenues 79% in Q4
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 5:35AM CDT
VCYT: 9.63 (+0.40)
Veracyte's (VCYT) CEO Bonnie Anderson on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 19, 10:03PM CDT
VCYT: 9.63 (+0.40)
Veracyte reports 4Q loss
Automated Insights - Thu Mar 19, 3:24PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Thursday reported a loss of $8.1 million in its fourth quarter.
VCYT: 9.63 (+0.40)
Veracyte misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 3:13PM CDT
VCYT: 9.63 (+0.40)
Veracyte, Inc. Announces Fourth Quarter and Full-Year 2014 Financial Results, Provides 2015 Financial Outlook
PR Newswire - Thu Mar 19, 3:05PM CDT
Veracyte, Inc. (Nasdaq: VCYT) today reported financial results and business progress for the quarter and full year ended December 31, 2014, and provided financial guidance for 2015.
VCYT: 9.63 (+0.40)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.05), VRTX: 133.20 (-2.62), CERU: 6.27 (+0.07), FOMX: 10.46 (-0.44), ONTX: 2.34 (-0.05), PFNX: 15.80 (-0.20), OMER: 24.32 (-0.35), PGNX: 6.03 (-0.38), SYN: 2.33 (+0.01), VCYT: 9.63 (+0.40), STEM: 0.61 (-0.21), APRI: 1.61 (-0.13), KPTI: 31.49 (-1.13)
Veracyte, Inc. to Announce Fourth Quarter and Full-Year 2014 Financial Results and Host Conference Call and Webcast on Thursday, March 19, 2015
PR Newswire - Thu Mar 12, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2014 financial results after close of market on Thursday, March 19, 2015. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and business progress.
VCYT: 9.63 (+0.40)
Veracyte Announces Publication of Data Demonstrating Analytical and Clinical Validity of Its Afirma® BRAF Malignancy Classifier
PR Newswire - Thu Feb 05, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of data demonstrating the analytical and clinical validity of Afirma® BRAF, the company's malignancy classifier for identifying BRAF V600E mutation status among thyroid nodule biopsies. The data, which appear in the current issue of Pacific Symposium on Biocomputing, confirm that the Afirma RNA-based classifier detects the BRAF V600E mutation with high diagnostic accuracy.
VCYT: 9.63 (+0.40)
Veracyte to Present at the Leerink Partners 2015 Global Healthcare Conference
PR Newswire - Wed Feb 04, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat discussion at the Leerink Partners 2015 Global Healthcare Conference on Wednesday, February 11, 2015 at 11:30 a.m. ET in New York, NY.
VCYT: 9.63 (+0.40)
5 Stocks Ready for Breakouts: Veracyte, Flextronics and More
at The Street - Fri Jan 30, 5:00AM CST
These stocks look poised to break out and trade higher from current levels.
FLEX: 12.35 (-0.18), EXXI: 4.16 (+0.06), VCYT: 9.63 (+0.40), XGTI: 0.21 (unch), RGLS: 17.49 (-0.80)
Veracyte, Inc. Names Dr. Robert S. Epstein to Its Board of Directors
PR Newswire - Mon Jan 12, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointment of Robert S. Epstein, M.D., M.S., to its Board of Directors.
VCYT: 9.63 (+0.40), ILMN: 189.59 (-3.01)
Veracyte to Present at the J.P. Morgan 33rd Annual Healthcare Conference
PR Newswire - Thu Jan 08, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the J.P. Morgan 33rd Annual Healthcare Conference on Thursday, January 15, 2015, at 8:30 a.m. Pacific Time in San Francisco, Calif.
VCYT: 9.63 (+0.40), JPM: 62.60 (-0.20)
